(Q64940048)

1 July 2019

title

Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. (English)

1 reference

1 July 2019

author

Sara Hildebrand

14

1 reference

1 July 2019

author name string

Ying Wang

1

1 reference

1 July 2019

Lijing Su

2

1 reference

1 July 2019

Matthew D Morin

3

1 reference

1 July 2019

Brian T Jones

4

1 reference

1 July 2019

Yuto Mifune

5

1 reference

1 July 2019

Hexin Shi

6

1 reference

1 July 2019

Kuan-Wen Wang

7

1 reference

1 July 2019

Xiaoming Zhan

8

1 reference

1 July 2019

Aijie Liu

9

1 reference

1 July 2019

Jianhui Wang

10

1 reference

1 July 2019

Xiaohong Li

11

1 reference

1 July 2019

Miao Tang

12

1 reference

1 July 2019

Sara Ludwig

13

1 reference

1 July 2019

Kejin Zhou

15

1 reference

1 July 2019

Daniel J Siegwart

16

1 reference

1 July 2019

Eva Marie Y Moresco

17

1 reference

1 July 2019

Hong Zhang

18

1 reference

1 July 2019

Dale L Boger

19

1 reference

1 July 2019

Bruce Beutler

20

1 reference

1 July 2019

publication date

27 August 2018

1 reference

1 July 2019

Proceedings of the National Academy of Sciences of the United States of America

published in

1 reference

1 July 2019

volume

115

1 reference

1 July 2019

issue

37

1 reference

1 July 2019

page(s)

E8698-E8706

1 reference

1 July 2019

Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity

cites work

1 reference

12 December 2020

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

1 reference

12 December 2020

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

12 December 2020

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

12 December 2020

Erythropoietin mimetics derived from solution phase combinatorial libraries

1 reference

12 December 2020

T cell activation by TLRs: a role for TLRs in the adaptive immune response

1 reference

12 December 2020

Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a tri-acylated lipopeptide

1 reference

12 December 2020

Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms

1 reference

12 December 2020

TLRs and innate immunity

1 reference

12 December 2020

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

1 reference

12 December 2020

Identification of novel synthetic toll-like receptor 2 agonists by high throughput screening

1 reference

12 December 2020

Vaccine adjuvants: putting innate immunity to work

1 reference

12 December 2020

TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells

1 reference

12 December 2020

TLR2-dependent induction of IL-10 and Foxp3+ CD25+ CD4+ regulatory T cells prevents effective anti-tumor immunity induced by Pam2 lipopeptides in vivo

1 reference

12 December 2020

TLR2 stimulation drives human naive and effector regulatory T cells into a Th17-like phenotype with reduced suppressive function.

1 reference

12 December 2020

TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.

1 reference

12 December 2020

Toll-like receptor signaling

1 reference

12 December 2020

Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy

1 reference

12 December 2020

Key roles of adjuvants in modern vaccines

1 reference

12 December 2020

Molecular mechanisms of TLR2-mediated antigen cross-presentation in dendritic cells

1 reference

12 December 2020

Toll-like receptor signaling pathways

1 reference

12 December 2020

Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice

1 reference

12 December 2020

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

12 December 2020

Specific activation of the TLR1-TLR2 heterodimer by small-molecule agonists.

1 reference

12 December 2020

Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling

1 reference

12 December 2020

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

1 reference

12 December 2020

Toll-like receptors: the swiss army knife of immunity and vaccine development

1 reference

12 December 2020

Overview of Vaccine Adjuvants: Introduction, History, and Current Status

1 reference

12 December 2020

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells

1 reference

12 December 2020

cGAS is essential for the antitumor effect of immune checkpoint blockade

1 reference

12 December 2020

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

1 reference

12 December 2020

The Novel Toll-Like Receptor 2 Agonist SUP3 Enhances Antigen Presentation and T Cell Activation by Dendritic Cells.

1 reference

12 December 2020

A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy.

1 reference

12 December 2020

Enhanced immunostimulatory activity of in silico discovered agonists of Toll-like receptor 2 (TLR2).

1 reference

12 December 2020

Converting Cold into Hot Tumors by Combining Immunotherapies

1 reference

12 December 2020

Toll-like receptor 2 ligand and interferon-γ suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.1809232115

1 reference

1 July 2019

PMC publication ID

6140543

1 reference

1 July 2019

PubMed publication ID

30150374

1 reference

1 July 2019